HOME >> BIOLOGY >> NEWS
Other highlights in the February 18 issue of JNCI

Two Studies Examine Aspirin for Cancer Prevention

Two studies in the February 18 issue of JNCI address the association between aspirin use and the risk of two different types of cancer.

In one study, Ellen T. Chang, Sc.D., of the Harvard School of Public Health, and colleagues examined the association between various pain relievers and the risk of Hodgkin's lymphoma. In a case-control study, participants were asked to report their average use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) and of acetaminophen over the previous 5 years. They found that the risk of Hodgkin's lymphoma was lower with regular aspirin use (2 or more tablets per week) than with non-regular aspirin use, and that there was no association between risk of Hodgkin's lymphoma and use of other non-aspirin NSAIDs, but the risk was higher with regular acetaminophen use.

"If aspirin use is indeed found to protect against Hodgkin's lymphoma, this relationship could afford insight into the pathogenesis of the disease and offer possible clues toward its prevention," the authors write.

In a second study, Chin Hur, M.D., of Massachusetts General Hospital, and colleagues examined the cost-effectiveness of aspirin as a chemoprevention strategy for esophageal cancer in patients with Barrett's esophagus. Patients with Barrett's esophagus are at an increased risk for esophageal cancer and, as such, often undergo periodic endoscopic screening. Aspirin use has been associated with a reduced risk of esophageal cancer, but the use of aspirin can cause bleeding and other harms.

Using a model analysis to compare the effectiveness and cost-effectiveness of aspirin for the chemoprevention of esophageal cancer in patients with Barrett's esophagus, Hur and colleagues found that aspirin therapy with or without endoscopic surveillance was both more effective (in terms of quality-adjusted life years) and cost less than no therapy or just endoscopic
'"/>

Contact: Katherine Arnold
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
17-Feb-2004


Page: 1 2 3

Related biology news :

1. Other highlights in the September 1 JNCI
2. Other highlights in the August 18 JNCI
3. Other highlights in the August 4 JNCI
4. Other highlights in the July 7 JNCI
5. Other highlights in the June 16 JNCI
6. Other Highlights in the June 2 JNCI
7. Other highlights in the May 19 JNCI
8. Other highlights in the May 5 JNCI
9. Other highlights of the March 17 issue of JNCI
10. Other highlights in the March 3 issue of JNCI
11. Other highlights in the February 4 issue of JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/2/2016)... , Feb. 2, 2016 This ... the bioinformatic market by reviewing the recent advances ... tools that drive the field forward. Includes forecast ... Identify the challenges and opportunities that exist ... and software solution developers, as well as IT ...
(Date:2/2/2016)... , Feb. 2, 2016  Based on ... Frost & Sullivan recognizes US-based Intelligent Retinal Imaging ... & Sullivan Award for New Product Innovation. IRIS, ... North America , is poised ... rapidly growing diabetic retinopathy market. The IRIS technology ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of ... ended December 31, 2015. --> ... increased 2 percent compared to the comparable quarter last year to ... was $35.0 million, or $0.93 per diluted share. ... first quarter of fiscal 2016 grew 9 percent over the prior ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... NX Prenatal Inc., a US based ... for early warning of adverse pregnancy outcomes, announced ... by Dr. Thomas McElrath of Brigham ... Medicine,s (SMFM) annual meeting held in ... The presentation reported initial positive top-line results regarding ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... that it has joined the Human Vaccines Project, a public-private partnership to ... cancer. , The Human Vaccines Project brings together leading pharmaceutical and ...
(Date:2/10/2016)... 2016  Allergan plc (NYSE: AGN ) a ... Saunders , Allergan,s CEO and President, will be featured ... at the RBC Capital Markets Healthcare Conference on Tuesday, ... New York Palace Hotel in New York, ... and can be accessed on Allergan,s Investor Relations web ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, a fully-integrated network ... two long-standing principal investigators (PI) to the roles of Chief Medical Officer, Clinical ... Dr. Laurence Chu, a Benchmark Research PI in the Austin office, will assume ...
Breaking Biology Technology:
Cached News: